Financials Nicox SA BOERSE MUENCHEN

Equities

NXOA

FR0013018124

Pharmaceuticals

Market Closed - BOERSE MUENCHEN 03:43:27 2024-04-26 pm EDT 5-day change 1st Jan Change
0.373 EUR -0.67% Intraday chart for Nicox SA -1.06% -13.56%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Capitalization 1 148.9 144.7 161.1 109.8 55.83 18.7 18.7
Enterprise Value (EV) 1 148.9 144.7 133 89.38 53.61 22.05 18.7
P/E ratio -8.08 x -7.02 x -8.06 x -2.18 x -1.78 x -1.25 x -1.56 x
Yield - - - - - - -
Capitalization / Revenue 37 x 21 x 18.1 x 15.2 x 17.1 x 5.25 x 2.03 x
EV / Revenue 37 x 21 x 14.9 x 12.4 x 16.4 x 5.25 x 2.03 x
EV / EBITDA -7.29 x -12.9 x -26.5 x -5.38 x -2.35 x -1.7 x -
EV / FCF - - -24,567,989 x -4,834,123 x - - -
FCF Yield - - -0% -0% - - -
Price to Book - - 1.59 x 1.45 x 1.04 x - -
Nbr of stocks (in thousands) 29,719 33,231 37,030 42,991 49,845 50,011 50,011
Reference price 2 5.010 4.355 4.350 2.555 1.120 0.3740 0.3740
Announcement Date 3/6/19 3/6/20 3/1/21 4/28/22 3/20/23 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Net sales 1 4.027 6.9 8.9 7.233 3.271 4.2 9.2
EBITDA 1 -20.42 -11.21 -5.017 -16.61 -22.86 -16.4 -
EBIT 1 -20.67 -18.33 -6.76 -46.01 -33.96 -16.46 -14.8
Operating Margin -513.24% -265.68% -75.96% -636.11% -1,038.18% -408.01% -160.87%
Earnings before Tax (EBT) 1 -18.28 -22.78 -18.07 -47.4 -30.29 -14.95 -14.8
Net income 1 -18.39 -18.92 -18.1 -43.76 -27.76 -14.97 -14.8
Net margin -456.69% -274.23% -203.35% -605.02% -848.64% -371.09% -160.87%
EPS 2 -0.6200 -0.6200 -0.5400 -1.170 -0.6300 -0.3000 -0.2400
Free Cash Flow - - -5.412 -18.49 - - -
FCF margin - - -60.81% -255.62% - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/6/19 3/6/20 3/1/21 4/28/22 3/20/23 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2019 S2 2020 S1 2020 S2 2021 Q1 2021 Q2 2021 S1 2021 Q3 2021 Q4 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3
Net sales 1 5.59 1.265 2.4 6.6 0.6 0.722 1.322 2.4 3.478 0.7 1.43 0.8 1.041 0.9 1.1 1.2 4.3 1.5 1.6
EBITDA - - - - - - - - - - - - - - - - - - -
EBIT - -13.04 - 0.868 - - -12.15 - - - - - - - - -3.92 - -4.5 -4.4
Operating Margin - -1,030.67% - 13.15% - - -919.21% - - - - - - - - -326.67% - -300% -275%
Earnings before Tax (EBT) - -18.23 - -3.489 - - -11.74 - - - - - - - - -3.62 - -4.5 -4.4
Net income - -18.17 - -3.491 - - -11.71 - - - -17.01 - - - - -3.62 - -4.5 -4.4
Net margin - -1,436.44% - -52.89% - - -886.01% - - - -1,189.23% - - - - -301.67% - -300% -275%
EPS 2 -0.0300 -0.5900 - - - - -0.3200 - - - - - - - -0.0700 -0.0700 - -0.0800 -0.0700
Dividend per Share - - - - - - - - - - - - - - - - - - -
Announcement Date 9/26/19 3/6/20 9/10/20 3/1/21 6/24/21 9/24/21 9/24/21 1/28/22 4/28/22 9/16/22 9/16/22 12/20/22 3/20/23 - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - 9.24 -
Net Cash position 1 - - 28.1 20.5 2.22 - -
Leverage (Debt/EBITDA) - - - - - -0.5633 x -
Free Cash Flow - - -5.41 -18.5 - - -
ROE (net income / shareholders' equity) - -17% -17.2% -49.6% -43.4% - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - 2.730 1.760 1.070 - -
Cash Flow per Share - - -0.1800 - - - -
Capex 1 0.23 0.06 0.02 0.01 0.04 0.12 0.19
Capex / Sales 5.66% 0.91% 0.22% 0.11% 1.28% 3.03% 2.07%
Announcement Date 3/6/19 3/6/20 3/1/21 4/28/22 3/20/23 - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.374 EUR
Average target price
1 EUR
Spread / Average Target
+167.38%
Consensus